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Background: Imported malaria is the principal, preventable, life-threatening infection among Canadians travelling
abroad. The Canadian Malaria Network supplies information and parenteral malaria therapy to healthcare providers
treating severe and complicated malaria and gathers surveillance information on these cases.
Methods: Data were collected on the characteristics, risk factors, and clinical outcomes of severe malaria cases in
Canada from June 2001 to December 2013.
Results: The need for parenteral therapy in Canada has increased in the last decade. The vast majority of cases are
reported from Ontario and Quebec and occur among travellers to and from Africa. Regardless of country of birth,
all persons originating from endemic and non-endemic countries are at a similar risk of malaria-related complications.
Overall use and appropriateness of pre-travel advice and chemoprophylaxis remains low. Most cases result from patient
delays in recognizing symptoms and seeking appropriate medical attention. Although some healthcare delays occurred
in a select number of cases, the majority of patients were diagnosed quickly and were appropriately treated with
parenteral therapy within a few hours of diagnosis.
Conclusions: Data from the Canadian Malaria Network provide insight into the characteristics of imported severe
and complicated malaria infections in Canada. Improved understanding of this population can help target risk
reduction strategies and interventions to limit personal susceptibility and healthcare treatment delays.
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Malaria is the principal, life-threatening, infection among
international travellers from Canada, and a frequent health
concern for individuals travelling between Canada and en-
demic regions. The majority of malaria infections in Canada
are imported and occur in new immigrants or Canadians
travelling to their region of origin to visit friends and rela-
tives (VFR) [1,2]. In 2009, 35% of Canadian travellers bound
to destinations other than the USA visited regions with a
risk of malaria, a 131% increase from 2000 [3]. Between
1991 and 2011, an average of 483 (range: 333–1032) mal-
aria cases per year were reported to the Public Health
Agency of Canada [4]. Many of these infections can be pre-
vented through pre-travel healthcare consultation, appro-
priate use of chemoprophylaxis, and personal protective
measures to prevent mosquito bites. Moreover, the conse-
quences of infection can be minimized through health care* Correspondence: amccarthy@ottawahospital.on.ca
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Risk of severe malaria is associated with Plasmodium
falciparum infection which progresses to severe disease,
leading to clinical complications such as coma, renal
failure, respiratory distress, or death [5]. Severe malaria
infection can occur when malaria is not treated rapidly
with appropriate anti-malarial therapy. Parenteral artesu-
nate, introduced to Canada in 2009, is the preferred
medication for the treatment of severe malaria due to P.
falciparum. Parenteral quinine is the alternative therapy
when artesunate is contra-indicated, or when the only
indication for parenteral therapy is failure to tolerate
oral therapy. Both drugs are made available in Canada
via the Canadian Malaria Network (CMN) through
Health Canada’s Special Access Programme that allows
practitioners to request access to drugs that are unavail-
able for sale in Canada [6-8].
The CMN is a national network of designated medical
centres of malaria expertise across Canada that supply in-
formation, rapidly distribute parenteral malaria therapy
and collect surveillance data on severe and complicatedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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malaria infections requiring parenteral therapy in Canada.
Therefore, with the aim of better understanding imported
severe malaria infections in the region, surveillance data
from CMN between 2001 and 2013 were analyzed to de-
scribe national trends, risk factors and delays associated
with accessing parenteral anti-malarial therapy across
Canada.Methods
Data collection
Data for cases accessing parenteral therapy were reported
to CMN’s coordinating site. Attending physicians are re-
quired to complete two case report forms, which are sup-
plied with the treatment medication [see Additional file 1]
Form A collects non-nominal information on patient
demographics, travel history, infection, and treatment de-
lays on day 1 of treatment. Form B collects follow-up infor-
mation on disease outcome (s), health care requirements,
drug utilization and adverse events seven days following
initial treatment administration. Both forms are available
on the CMN website.Definitions
Severe malaria is defined by the clinical features established
at the World Health Organization (WHO) that includes:
History of recent possible exposure and no other related
pathology OR asexual forms of Plasmodium falciparum on
blood smear AND any one or more of the following
features: hyperparasitemia (>2% in non-immune, >5%
in semi-immune); impaired consciousness or coma;
prostration (unable to walk or sit up without assistance);
multiple convulsions (>2 in 24hrs); respiratory distress
(acidotic breathing); respiratory failure/pulmonary edema/
ARDS; circulatory collapse/shock (SBP<80mmHg adults
and <50mmHg children); acute kidney injury/renal failure
(Cr >265μmol/L or >upper limit for age for children);
jaundice (total bilirubin >45μmol/L); abnormal spon-
taneous bleeding/DIC; hypoglycemia (<2.2mmol/L);
metabolic acidosis/acidemia (pH<7.25, HCO3<15m-
mol/L); severe anemia (< 50g/L, in children; <70g/dL,
in adults); hemoglobinuria (macroscopic); hyperlacta-
taemia (lactate >5mmol/L) [7]. Complicated malaria is
defined as malaria infection in an individual who can-
not tolerate oral treatment (e.g., vomiting), without
clinical features of severe disease.
All case reports submitted to CMN were reviewed by
a tropical medicine physician (AM) to establish treat-
ment and chemoprophylaxis appropriateness [7]. Appro-
priate indication for parenteral anti-malarial treatment
was classified as complicated malaria or severe malaria
infection [7]. Chemoprophylaxis regimen appropriate-
ness was established by travel destination and preventionguidelines published by the Committee to Advise on
Tropical Medicine and Travel (CATMAT) [9].
Patient birth countries were classified as malaria-endemic
(mBC) or non-malaria-endemic (non-mBC) using the
WHO list of malaria-endemic countries [10].
Patient delays were defined as days between symptom
onset and initial Canadian physician visit. Healthcare
system delays were defined as: 1) days between the first
physician visit and laboratory-confirmed malaria diagnosis;
2) hours between laboratory-confirmed diagnosis and
CMN treatment request; 3) hours between treatment re-
quest and treatment receipt; and, 4) hours between treat-
ment receipt and treatment administration. All delays are
described as median values.
Therapy-related adverse events were classified as
minor, serious or other. Minor adverse events were de-
fined as symptoms of fatigue, dizziness and occasional
tinnitus. Serious adverse events were defined as haemolysis,
hypotension and delayed hemolysis. Delayed hemolysis was
defined as hemolysis that occurred 1 - 3 weeks after initi-
ation of treatment. Other adverse events were considered
to be adverse outcomes unrelated to parental anti-malarial
therapy alone and classified by the tropical medicine phys-
ician (AM) reviewing case forms.
Data analysis
Data analysis was performed using Stata 13 [11]. Cases
were separated by patient birth country and IV anti-
malarial drug type. Results were compared using t-test,
Chi-square test and Fisher’s exact test. Statistical signifi-
cance was set at p <0.05.
Results
Between June 2001 and December 2013, 293 patients
accessed IV quinine and/or artesunate treatment
through CMN. Of these, 248 (85%) were treated for se-
vere malaria, 31 (11%) for complicated malaria and 14
(5%) had neither severe nor complicated malaria and
were classified as inappropriately treated. Overall, 95%
(279) of parenteral treatment requests to CMN were ap-
propriate (Table 1). Unless otherwise indicated, the
remaining results focus on patients with severe malaria.
Severe malaria
The overall incidence of severe malaria in Canada during
the study period was 54 cases per 1,000 surveillance
days. There was a gradual increase in annual incidence
over time with the greatest number of cases occurring in
2013 (Table 1). Most Canadian provinces, with the ex-
ception of Prince Edward Island and the Territories,
have requested treatment for one or more cases of se-
vere malaria. The majority of requests (76%) occurred in
Ontario and Quebec (Figure 1). Most requests for IV
Table 1 Malaria cases treated through the CMN by appropriateness of IV therapy
Year Total cases no. IV therapy appropriate IV therapy
inappropriate
no. (%)
Severe malaria no. (%) Complicated malaria no. (%)
2001 15 13 (87) 2 (13) 0 (0)
2002 7 7 (100) 0 (0) 0 (0)
2003 13 8 (62) 3 (23) 2 (15)
2004 20 14 (70) 5 (25) 1 (5)
2005 12 11 (92) 0 (0) 1 (8)
2006 16 13 (81) 3 (19) 0 (0)
2007 16 13 (81) 2 (13) 1 (6)
2008 20 16 (80) 4 (20) 0 (0)
2009 23 20 (87) 3 (13) 0 (0)
2010 34 30 (88) 2 (6) 2 (6)
2011 30 25 (83) 5 (17) 0 (0)
2012 33 29 (88) 0 (0) 4 (12)
2013 54 49 (91) 2 (4) 3 (6)
TOTAL 293 248 (85) 31 (11) 14 (5)
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Demographics and risk factors
Severe malaria case demographic characteristics and
travel-related risk factors are summarized in Tables 2
and 3. The majority of severe malaria cases (53%) oc-
curred among mBC by visits to and from Africa (89%).
The greatest percentage of cases originated from Ghana
(12%), Nigeria (11%), Cameroon (7%) and Uganda (7%)Figure 1 Distribution of severe malaria cases by Canadian province
and territory (n = 248). Legend: AB= Alberta, BC = British Columbia,
MB = Manitoba, NB = New Brunswick, NL = Newfoundland & Labrador,
NS = Nova Scotia, NT = Northwest Territories, NU = Nunavut, ON =
Ontario, PE = Prince Edward Island, QC = Quebec, SK = Saskatchewan,
YT = Yukon.(Figure 2). Plasmodium falciparum accounted for 94% of
severe malaria infections. Although 36% accessed pre-
travel advice and 23% reported chemoprophylaxis use,
only 55% of chemoprophylaxis regimens were classified
as appropriate.
There were no statistically significant differences
among severe malaria cases of non-mBC and mBC with
respect to region of exposure, appropriateness of chemo-
prophylaxis regimens, species of infection or time to
parasite clearance. However, mBC cases were younger
(median age mBC 33 years vs non-mBC 41 years), less
likely to have accessed pre-travel advice (mBC 19% vs
non-mBC 56%), less likely to use chemoprophylaxis
(mBC 16% vs non-mBC 31%) and more likely to report
VFR (mBC 65% vs non-mBC 18%) as the predominant
reason for travel. Although not statistically significant, a
greater proportion of mBC travellers were children, female
and reported a longer median length of travel.
Diagnosis and treatment delays
Patient and healthcare system delays are summarized in
Table 4. The median time between landing in Canada to
illness was seven days. Patients waited a median of three
days following symptom onset to seek medical treatment.
Following first presentation to a Canadian physician,
most infections were laboratory confirmed within 24 hours.
A 45-minute delay occurred between diagnosis and paren-
teral treatment request from CMN, a 1.5-hour delay oc-
curred between treatment request from CMN and receipt
of IV drug and a 1-hour delay occurred from receipt of the
drug to treatment administration. Collectively, these delays
result in a median healthcare system delay of two or more
hours from presentation to treatment.
Table 2 Socio-demographics of severe malaria cases
All severe cases no./no. (%) non-mBC no./no. (%) mBC no./no. (%) P value
Male 137/245 (56) 70/115 (61) 67/130 (52) 0.142
Age, years, median (range) 38 (0–77) 41 (0–77) 33 (1–74) 0.002
Children (<18 years) 45/248 (18) 15/116 (13) 30/132 (23) 0.046
Residency
Canadian resident 197/245 (80) 109/115 (95) 88/130 (68) 0.000
Recent immigranta 29/245 (12) 0/115 (0) 29/130 (22) 0.000
Visitor 16/245 (7) 3/115 (3) 13/130 (10) 0.019
Other 3/245 (1) 3/115 (3) 0/130 (0) 0.064
Abbreviations: non-mBC not born in malaria-endemic country, mBC born in malaria-endemic country.
aA recent immigrant was defined as an individual who immigrated within the last year.
Table 3 Travel characteristics among severe malaria cases
Characteristic All severe cases no./no. (%) non-mBC no./no. (%) mBC no./no. (%) P value
Reason for travel
Visiting friends and relatives 97/214 (45) 16/89 (18) 81/125 (65) 0.000
Business 40/214 (19) 34/89 (38) 6/125 (5) 0.000
Immigration 34/214 (16) 1/89 (1) 33/125 (26) 0.000
Vacation 29/214 (14) 23/89 (26) 6/125 (5) 0.000
Volunteer 20/214 (9) 17/89 (19) 3/125 (2) 0.000
Education 9/214 (4) 3/89 (3) 6/125 (5) 0.608
Military 0/214 (0) 0/89 (0) 0/125 (0) -
Medical 0/214 (0) 0/89 (0) 0/125 (0) -
Other 8/214 (4) 4/89 (4) 4/125 (3) 0.623
Region of travel
Africa 220/248 (89) 100/116 (86) 120/132 (91) 0.243
Central & South America 10/248 (4) 7/116 (6) 3/132 (2) 0.133
Caribbean 7/248 (3) 3/116 (3) 4/132 (3) 0.833
Asia 9/248 (4) 4/116 (3) 5/132 (4) 0.887
Oceania 2/248 (1) 2/116 (2) 0/132 (0) 0.130
Length of travel, days, median (range) 31 (4–946) 31 (4–536) 35 (5–946) 0.599
Pre-travel advice obtained 78/216 (36) 55/98 (56) 23/118 (19) 0.000
Chemoprophylaxis used 55/239 (23) 35/112 (31) 20/127 (16) 0.000
Chemoprophylaxis appropriate 30/55 (55) 20/35 (57) 10/20 (50) 0.791
Infection species
P. falciparum 229/244 (94) 105/114 (92) 124/130 (95) 0.287
P. vivax 9/244 (4) 5/114 (4) 4/130 (3) 0.588
P. malariae 1/244 (0) 1/114 (1) 0/130 (0) 0.285
P. ovale 2/244 (1) 1/114 (1) 1/130 (1) 0.926
P. knowlesi 0/244 (0) 0/114 (0) 0/130 (0) -
Unknown 10/244 (4) 6/114 (5) 4/130 (3) 0.390
Abbreviations: non-mBC not born in malaria-endemic country, mBC born in malaria-endemic country.
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Figure 2 Severe malaria cases in Canada, by country of acquisition (n = 246).
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treatment request and receipt of IV drug was observed
between cases presenting in cities with a CMN site or
satellite centre (1 hour) versus cities that did not have a
CMN centre (2.8 hours). This time difference was not
statistically significant.
Treatment requested
Among severe malaria cases, 116 (47%) were treated
with IV quinine and 129 (52%) were treated with IV
artesunate; both drugs were requested for three cases for
which each was initially started on IV quinine, and were
changed to IV artesunate therapy (1.0%). In one case
treatment was switched to artesunate due to increased
QTc with IV quinine, in two other cases quinine was
given, since it was in stock, while awaiting transfer of
artesunate from another hospital. Since the introduction
of IV artesunate to Canada in 2009, the proportion of se-
vere malaria cases treated with IV artesunate has in-
creased rapidly as the treatment of choice (Figure 3).
Symptom presentation
The most commonly reported clinical features of severe
malaria include: hyperparasitaemia (70%), jaundice (29%),Table 4 Time delays associated with access to health care and
Delay Mean
Patient (days)
Date of illness to first MD visit (n=229) 4.2
Healthcare system (hours)
Time from MD visit to lab diagnosis (n=229) 30.2
Time from diagnosis to contact CMN (n=90) 2.0
Time from contact to receive IV drug (n=133) 2.2
Time from receipt to drug administration (n=18) 1.2
Total healthcare system delay (n=248) 29.9
Abbreviations: SD standard deviation.
aTwo cases had delays of greater than 30 days.
bFive cases had delays of 9 days to a maximum of 35 days. Delays due to: P.vivax in
cElevated numbers for the same reason as explained inb.impaired consciousness or coma (27%) (Table 5). In
addition, vomiting was reported as a symptom of malaria in
25% of severe malaria cases.
Hospitalization
CMN collects information on hospitalization, malaria
complications and drug adverse events on Form B. Form
B was completed for 43% of all patients accessing IV
therapy, and in 60% of severe malaria cases (Table 6).
There were no clinical or statistically significant differ-
ences between mBC and non-mBC cases for length of
hospitalization, days to negative smear, length of inten-
sive care unit (ICU) stay, administration of step-down
therapy, supportive treatments, outcome or adverse
events. Median time to a negative blood smear following
treatment was three days among severe malaria patients.
Cases spent a median of four days in hospital and a me-
dian one day in ICU. The majority of severe cases (87%)
were prescribed at least one form of step-down therapy.
Adverse events
Adverse events related to parenteral therapy were re-
ported by 11% of severe malaria cases. Adverse events








fection, unavailability of microbiologists.
Figure 3 Severe malaria cases in Canada per year by type of IV parenteral therapy requested.
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tinnitus) were reported in 7% of patients treated with
quinine and 2% of those treated with artesunate. Serious
adverse events were reported by 3% of cases (n=4) and
involved a single case of hypotension and ischemic en-
cephalopathy related to IV quinine, two cases of delayed
haemolysis, and one case of early haemolysis associated
with IV artesunate. Five per cent of severe cases reported
adverse events classified as ‘other’ but were determined
by the CMN physician (AM) to be unrelated to IV
therapy alone and included nausea, vomiting and vividTable 5 Severe malaria cases by indication for IV therapy
IV Indication No./no. (%)
Hyperparasitemia 173/248 (70)
Jaundice 72/248 (29)
Impaired consciousness or coma 68/248 (27)
Vomiting 61/248 (25)
Circulatory collapse/shock 40/248 (16)
Hemoglobinuria 33/248 (14)
Acute kidney injury/renal failure 34/248 (13)
Metabolic acidosis/acidemia 33/248 (13)
Respiratory distress 29/248 (12)
Abnormal spontaneous bleeding/DIC 17/248 (7)
Severe anemia 17/248 (7)
Hypoglycemia 14/248 (6)
Respiratory failure/Pulmonary edema/ARDS 6/248 (2)
Multiple convulsions 4/248 (2)
Hyperlactataemia 4/248 (2)
Prostration 3/248 (1)
Other 41/248 (17)dreams. No adverse events resulted in death. For a
brief case summary of the severe drug-associated ad-
verse events, see Additional file 2.Fatalities
Three fatalities occurred among severe and complicated
malaria cases. All deaths occurred in mBC or VFR trav-
ellers. None of the reported deaths occurred in children.
No fatalities were related to adverse events or complica-
tions from parenteral therapy. For a brief case summary
of each fatality, see Additional file 2.Discussion
This study describes national trends, demographic char-
acteristics, risk factors, and delays associated with all
cases of severe and complicated malaria reported to
CMN. CMN data demonstrate a gradual increase in an-
nual incidence of severe malaria over time. This trend is
consistent with results observed in the USA reported by
the 2011 Morbidity and Mortality Weekly Report malaria
surveillance summary [12]. The increase may be attributed
to increased global travel and immigration [1,13].
In Canada there were slightly more severe malaria in-
fections (18%) among children under age 18 years than
in the USA (16%). Canada also had a higher percentage
of severe cases with P. falciparum infection (94%), com-
pared to 74% in the USA; however it is important to
note that a species was identified and reported in 94% of
Canadian cases versus only 77% in USA cases.
Most severe malaria cases identified Canada as their
primary country of residence (80%) and in the USA, 75%
identified the USA as their country of residence. Compared
to the USA, a smaller proportion of Canadian travellers
Table 6 Outcomes of severe malaria casesa
All severe cases no./no. (%) IV-Artesunate no./no. (%) IV-Quinine no./no. (%) P value
Hospitalization, days, median (range) (n=133) 4 (0–28) 4 (0–28) 4 (0–27) 0.070
Intensive care unit stay, days, median (range) (n=134) 1 (0–19) 0 (0–17) 3 (0–19) 0.045
Negative blood smear, days, median (range) (n=104) 3 (0–21) 2 (0–8) 4 (1–21) 0.000
Stepdown therapy 130/150 (87) 88/99 (89) 42/51 (82) 0.265
IV adverse events 15/131 (11) 7/89 (8) 8/42 (19) 0.061
Minor complication 5/131 (4) 2/89 (2) 3/42 (7) 0.327
Serious complication 4/131 (3) 3/89 (3) 1/42 (2) 1.000
Other complication 6/131 (5) 2/89 (2) 4/42 (10) 0.083
Outcome
Still hospitalized 27/143 (18) 16/92 (17) 11/51 (22) 0.514
Discharged 100/143 (70) 64/92 (70) 36/51 (71) 0.898
Deceased 3/143 (2) 1/92 (1) 2/51 (4) 0.257
aThree cases were started on IV quinine and transferred to IV artesunate. To simplify analysis, those cases were classified as having received IV artesunate therapy
alone. None had adverse events or negative outcomes.
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sus 59% in the USA.
The vast majority of severe and complicated malaria
cases were reported from the most populated Canadian
provinces of Quebec and Ontario, and occurred among
travellers to and from Africa. These findings are consist-
ent with the latest reports from Statistics Canada that
state the highest proportions of new/recent immigrants
to Canada reside in Quebec and Ontario, and originate
from malaria-endemic regions such as Africa, Asia and
Pacific, and South and Central Americas [14].
It was demonstrated that an individual’s country of
birth is not a risk factor for malaria, indicating Canadian
residents originating from mBC and non-mBC are at
similar risk of malaria-related complications. Although
more individuals from non-endemic birth countries re-
ported accessing pre-travel advice, the overall use of ap-
propriate and effective chemoprophylaxis was minimal
at 13% (37/280) among all cases treated with IV therapy.
Experts believe diagnosis and treatment delays attrib-
uted to the non-specific symptomatology and unpredict-
able clinical complications of infection are the primary
cause of severe infections in non-endemic regions, like
Canada [15-18]. Patient delays of approximately three days
occurred among reported cases. This finding highlights
the importance of emphasizing malaria prevention and
pre-travel health consultation prior to international travel,
especially among VFR travellers heading to endemic re-
gions [19]. Pre-travel consultations should inform travel-
lers of malaria symptoms and outline the importance of
seeking immediate medical attention should malaria
symptoms develop. This same information should also be
distributed to recent immigrants to Canada from malaria-
endemic areas.Even though the majority of severe malaria cases were
diagnosed quickly and appropriately treated with paren-
teral therapy within a few hours of presentation to a
Canadian physician, better health care provider know-
ledge of malaria symptoms (by travellers and health care
practitioners) and reduced delays in access to effective
therapy may reduce the number of cases that progress
to severe disease. Furthermore, health care providers
should educate Canadian VFR travelers of their malaria
risk and loss of acquired malaria immunity over time
during pre-travel medical visits.
Limitations of this analysis stem from missing data and
gaps in the existing CMN dataset. A large number of case
report forms were missing key information, and nearly half
(43%) of the follow-up Form B were never submitted to
CMN. As a result, presentation of a complete picture of
malaria treatment procedures and outcomes, complications
or adverse effects was not possible. Furthermore, given that
Form B is collected 7 days following treatment initiation,
cases of delayed hemolysis may not have been reported to
CMN. Incomplete reporting of data highlights the import-
ance of physician engagement in CMN surveillance activ-
ities in order to improve the availability and delivery of
anti-malaria medications to patients. Additionally, the study
sample was limited to patients treated with IV malaria ther-
apies in Canada provided through the CMN. Therefore, the
ability to capture information on additional cases of severe
malaria with other treatments was limited, such as ex-
change therapy not possible.
Conclusions
These findings demonstrate the utility of pre-positioning
effective parenteral malaria therapy across the country
through the CMN. The current trend of increased travel
McCarthy et al. Malaria Journal  (2015) 14:151 Page 8 of 8to endemic areas will increase the number of cases of se-
vere malaria in Canada. These cases will continue to
augment the need for access to parenteral therapy. There is
a need for better travel health strategies to improve the up-
take of pre-travel consultation and knowledge of malaria
symptoms. These findings can inform the development of
improved travel health practices and policies across
Canada, and can be used to justify the development of such
strategies in other non-endemic countries managing indi-
viduals with travellers’ malaria. Ideally, better education of
travellers visiting malaria-endemic areas, especially VFR
travelers returning to their country of origin, will result in
faster treatment-seeking behaviour, leading to earlier diag-
nosis and effective therapy, thus minimizing the risk of
severe disease.Additional files
Additional file 1: Forms used by physicians for the monitoring of
parenteral therapy for severe malaria.
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